12 April 2021 in Cancer Discovery
Sequence alterations in microsatellites and an elevated mutational burden are observed in 20% of gastric cancers and associated with clinical response to anti–PD-1 antibodies. However, 50% of microsatellite instability–high (MSI-H) cancers are intrinsically resistant to PD-1 therapies. We conducted a phase II trial of pembrolizumab in patients with advanced MSI-H gastric cancer and included serial and multi-region tissue samples in addition to serial peripheral blood analyses. The number of whole-exome sequencing (WES)–derived nonsynonymous mutations correlated with antitumor activity and prolonged progression-free survival (PFS). Coupling WES to single-cell RNA sequencing, we identified dynamic tumor evolution with greater on-treatment collapse of mutational architecture in responders. Diverse T-cell receptor repertoire was associated with longer PFS to pembrolizumab. In addition, an increase in PD-1+ CD8+ T cells correlated with durable clinical benefit. Our findings highlight the genomic, immunologic, and clinical outcome heterogeneity within MSI-H gastric cancer and may inform development of strategies to enhance responsiveness. Significance: This study highlights response heterogeneity within MSI-H gastric cancer treated with pembrolizumab monotherapy and underscores the potential for extended baseline and early on-treatment biomarker analyses to identify responders. The observed markers of intrinsic resistance have implications for patient stratification to inform novel combinations among patients with intrinsically resistant features. See related commentary by Fontana and Smyth, p. 2126. This article is highlighted in the In This Issue feature, p. 2113
21 December 2021 in Cancer Discovery
Chemotherapy is ubiquitous in first-line treatment of advanced gastric cancer, yet responses are heterogeneous, and little is known about mediators of chemotherapy response. To move forward, an understanding of the effects of standard chemotherapy on the tumor–immune microenvironment (TME) is needed. Coupling whole-exome sequencing, bulk RNA and single-cell transcriptomics from paired pretreatment and on-treatment samples in treatment-naïve patients with HER2-positive and HER2-negative gastric cancer, we define features associated with response to platinum-based chemotherapy. Response was associated with on-treatment TME remodeling including natural killer (NK) cell recruitment, decreased tumor-associated macrophages, M1-macrophage repolarization, and increased effector T-cell infiltration. Among chemotherapy nonresponders, we observed low/absent PD-L1 expression or modulation, on-treatment increases in Wnt signaling, B-cell infiltration, and LAG3-expressing T cells coupled to an exodus of dendritic cells. We did not observe significant genomic changes in early on-treatment sampling. We provide a map of on-treatment TME modulation with standard chemotherapy and nominate candidate future approaches. Significance: Using paired pretreatment and on-treatment samples during standard first-line chemotherapy, we identify chemotherapy-induced NK-cell infiltration, macrophage repolarization, and increased antigen presentation among responders. Increased LAG3 expression and decreased dendritic cell abundance were seen in nonresponders, emphasizing remodeling of the TME during chemotherapy response and resistance. This article is highlighted in the In This Issue feature, p. 873
6 February 2024 in Cancer Discovery
Adding anti–programmed cell death protein 1 (anti–PD-1) to 5-fluorouracil (5-FU)/platinum improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To understand the effects of chemotherapy and immunotherapy, we conducted a phase II first-line trial (n = 47) sequentially adding pembrolizumab to 5-FU/platinum in advanced GEA. Using serial biopsy of the primary tumor at baseline, after one cycle of 5-FU/platinum, and after the addition of pembrolizumab, we transcriptionally profiled 358,067 single cells to identify evolving multicellular tumor microenvironment (TME) networks. Chemotherapy induced early on-treatment multicellular hubs with tumor-reactive T-cell and M1-like macrophage interactions in slow progressors. Faster progression featured increased MUC5A and MSLN containing treatment resistance programs in tumor cells and M2-like macrophages with immunosuppressive stromal interactions. After pembrolizumab, we observed increased CD8 T-cell infiltration and development of an immunity hub involving tumor-reactive CXCL13 T-cell program and epithelial interferon-stimulated gene programs. Strategies to drive increases in antitumor immune hub formation could expand the portion of patients benefiting from anti–PD-1 approaches. Significance: The benefit of 5-FU/platinum with anti–PD-1 in first-line advanced gastric cancer is limited to patient subgroups. Using a trial with sequential anti–PD-1, we show coordinated induction of multicellular TME hubs informs the ability of anti–PD-1 to potentiate T cell–driven responses. Differential TME hub development highlights features that underlie clinical outcomes. This article is featured in Selected Articles from This Issue, p. 695
26 January 2017 in Helicobacter
2 December 2018 in Alimentary Pharmacology & Therapeutics
Summary: Background: Although a higher risk of other immune‐mediated diseases has been reported in inflammatory bowel disease (IBD) patients, the risk factors of immune‐mediated diseases development and the effect of concomitant immune‐mediated diseases on outcomes remain poorly defined.Aim: To determine the risk factors of incident immune‐mediated diseases and the impact of comorbid immune‐mediated diseases on outcomes in IBD.Methods: Using the National Health Insurance claims data for the entire Korean population, we identified 35 581 IBD patients without immune‐mediated diseases and 595 IBD patients with immune‐mediated diseases from 2012 to 2013, and follow‐up until 2016. We selected four controls by age and sex for comparing with cases.Results: A total of 35 581 IBD patients without immune‐mediated diseases and 142 324 matched controls without immune‐mediated diseases were followed from 2014 to 2016 and of these 239 IBD patients and 357 controls developed immune‐mediated disease. The overall immune‐mediated diseases risk was higher in IBD patients (HR, hazard ratio, 2.47; 95% confidence interval, CI, 2.09‐2.91). In a nested case‐control study of the IBD cohort, adult patients aged ≥20 years and frequent hospitalisation ≥1 per year were independent risk factors for incident immune‐mediated diseases, in contrast, 5‐aminosalicylic acid (5‐ASA) use had protective effect (odds ratio, 0.61; 95% CI, 0.41‐0.90) for developing immune‐mediated diseases. In addition, IBD patients with another immune‐mediated disease had an increased risk of needing anti‐TNF‐α agent (HR, 2.40; 95% CI, 2.02‐2.84) and developing acute flare (HR, 1.76; 95% CI, 1.37‐2.26).Conclusions: The incidence of immune‐mediated diseases in IBD patients was higher than that of non‐IBD population. 5‐ASA use may reduce this risk.
27 March 2017 in Atherosclerosis